Health
Emyria to seek approval for trial evaluating MDMA to treat PTSD – Stockhead
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder…
Link copied toclipboard
Nine years after a potentially groundbreaking Australian clinical trial evaluating the use of the psychoactive drug molly to treat post-traumatic stress disorder was rejected on ethics grounds, an ASX-listed drug development company is taking another crack at it.
Emyria (ASX:EMD) announced this morning that in partnership with Mind Medicine Australia it would seek approval for a major clinical trial testing the use of MDMA to alleviate treatment-resistant PTSD.
Emyria managing…
Continue Reading
